N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2

US10968235B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Christine Hiu-Tung Chen · Waltham, US
• Zhuoliang Chen · Cambridge, US
• Michael Dore · Saint-Bruno-de-Montarville, CA
• Jorge Garcia Fortanet · Wilmington, US
• John William Giraldes · Milford Mill, US
• Rajesh Karki · Quincy, US
• Mitsunori Kato · Cambridge, US
• Matthew J. LaMarche · Reading, US
• Lawrence Blas Perez · Silver Spring, US
• Martin Sendzik · Belmont, US
• Troy Douglas Smith · Nashua, US
• Bakary-Barry Toure · Weston, US
• Sarah Williams · Emeryville, US

Key dates

• Filing date: May 21, 2019
• Grant date: Apr 6, 2021
• Expiry date: May 21, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/07
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.